Volume 15, Issue 8 · IJARST · ISSN 2319-1783 / 2320-1126

A Next-Generation Drug Discovery Using Artificial Intelligence: Achievements and Challenges

A Next-Generation Drug Discovery Using Artificial Intelligence: Achievements and Challenges is an open-access, peer-reviewed research paper by Pranjal Ajit Jadhav, Dr. Rupesh Ashok Pingale, Kanchan Gajanan Gawai, Samrudhi Deepak Bhand, published in Volume 15, Issue 8 of the International Journal of Advanced Research in Science and Technology (IJARST), a UGC-approved journal (Print ISSN 2319-1783, Online ISSN 2320-1126).

Author

Pranjal Ajit Jadhav, Dr. Rupesh Ashok Pingale, Kanchan Gajanan Gawai, Samrudhi Deepak Bhand

Abstract

Artificial intelligence is revolutionizing drug discovery by accelerating target identification, molecular design, virtual screening, and toxicity prediction, while tackling longstanding challenges like high costs and lengthy timelines in traditional pipelines. This review explores recent AI innovations—such as AlphaFold for protein structure prediction, generative models for de novo drug design, and graph neural networks for drug repurposing—alongside real-world case studies from companies like Exscientia, Insilico Medicine, and BenevolentAI, which have produced clinical candidates like DSP-1181 and rentosertib. Despite these advances, key hurdles persist, including data quality issues, model interpretability, synthetic feasibility for complex molecules, and integration with experimental workflows, underscoring the need for explainable AI, better datasets, and ethical frameworks to bridge research gaps. Looking ahead, hybrid AI-experimental approaches and collaborations between pharma giants and AI startups promise to deliver safer, more personalized therapies faster.

Keywords: Artificial Intelligence (AI), Computational Drug Design, Data Augmentation, De Novo Drug Design, Drug Development Pipeline.

DOI: https://doi.org/10.62226/ijarst20262785

 

REFERENCES

1. Blanco-Gonzalez A, Cabezon A, Seco-Gonzalez A, Conde-Torres D, Antelo-Riveiro P, Pineiro A, Garcia-Fandino R. The role of AI in drug discovery: challenges, opportunities, and strategies. Pharmaceuticals. 2023 Jun 18;16(6):891.
2. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, Li B, Madabhushi A, Shah P, Spitzer M, Zhao S. Applications of machine learning in drug discovery and development. Nature reviews Drug discovery. 2019 Jun;18(6):463-77.
3. Moingeon P, Kuenemann M, Guedj M. Artificial intelligence-enhanced drug design and development: Toward a computational precision medicine. Drug discovery today. 2022 Jan 1;27(1):215-22.
4. Baltrušaitis T, Ahuja C, Morency LP. Multimodal machine learning: A survey and taxonomy. IEEE transactions on pattern analysis and machine intelligence. 2018 Jan 25;41(2):423-43.
5. Qureshi R, Irfan M, Gondal TM, Khan S, Wu J, Hadi MU, Heymach J, Le X, Yan H, Alam T. AI in drug discovery and its clinical relevance. Heliyon. 2023 Jul 1;9(7).
6. Mamoshina P, Volosnikova M, Ozerov IV, Putin E, Skibina E, Cortese F, Zhavoronkov A. Machine learning on human muscle transcriptomic data for biomarker discovery and tissue-specific drug target identification. Frontiers in genetics. 2018 Jul 12;9:242.
7. Qureshi R, Zou B, Alam T, Wu J, Lee VH, Yan H. Computational methods for the analysis and prediction of egfr-mutated lung cancer drug resistance: Recent advances in drug design, challenges and future prospects. IEEE/ACM Transactions on Computational Biology and Bioinformatics. 2022 Jan 10;20(1):238-55.
8. Sliwoski G, Kothiwale S, Meiler J, Lowe Jr EW. Computational methods in drug discovery. Pharmacological reviews. 2014 Jan 1;66(1):334-95.
9. Costa PR, Acencio ML, Lemke N. A machine learning approach for genome-wide prediction of morbid and druggable human genes based on systems-level data. BMC genomics. 2010 Dec 22;11(Suppl 5):S9.
10. Khan JY, Khondaker MT, Hoque IT, Al-Absi HR, Rahman MS, Guler R, Alam T, Rahman MS. Toward preparing a knowledge base to explore potential drugs and biomedical entities related to COVID-19: automated computational approach. JMIR medical informatics. 2020 Nov 10;8(11):e21648.
11. Álvarez-Machancoses Ó, Fernández-Martínez JL. Using artificial intelligence methods to speed up drug discovery. Expert opinion on drug discovery. 2019 Aug 3;14(8):769-77.
12. Zang Q, Mansouri K, Williams AJ, Judson RS, Allen DG, Casey WM, Kleinstreuer NC. In silico prediction of physicochemical properties of environmental chemicals using molecular fingerprints and machine learning. Journal of chemical information and modeling. 2017 Jan 23;57(1):36-49.
13. Nicolaou CA, Brown N. Multi-objective optimization methods in drug design. Drug Discovery Today: Technologies. 2013 Sep 1;10(3):e427-35.
14. Sachdev K, Gupta MK. A comprehensive review of feature based methods for drug target interaction prediction. Journal of biomedical informatics. 2019 May 1;93:103159.
15. Shi Y, Ren P, Zhang YI, Gong X, Hu M, Liang H. Information extraction from FDA drug Labeling to enhance product-specific guidance assessment using natural language processing. Frontiers in research metrics and analytics. 2021 Jun 10; 6:670006.
16. Khalil Zadeh N, Sepehri MM, Farvaresh H. Intelligent sales prediction for pharmaceutical distribution companies: A data mining-based approach. Mathematical Problems in Engineering. 2014;2014(1):420310.
17. Sim JA, Huang X, Horan MR, Stewart CM, Robison LL, Hudson MM, Baker JN, Huang IC. Natural language processing with machine learning methods to analyze unstructured patient-reported outcomes derived from electronic health records: A systematic review. Artificial intelligence in medicine. 2023 Dec 1; 146:102701.
18. Yan Y, Zhao Y, Yao H, Feng J, Liang L, Han W, Xu X, Pu C, Zang C, Chen L, Li Y. RPBP: deep retrosynthesis reaction prediction based on byproducts. Journal of Chemical Information and Modeling. 2023 Sep 19;63(19):5956-70.
19. Yin H, Sharma B, Hu H, Liu F, Kaur M, Cohen G, McConnell R, Eckel SP. Predicting the climate impact of healthcare facilities using gradient boosting machines. Cleaner environmental systems. 2024 Mar 1;12:100155.
20. Wilde AM, Song M, Allen WP, Junkins AD, Frazier JM, Moore SE, Schulz PS. Implementation of a pharmacy-driven rapid bacteremia response program. American Journal of Health-System Pharmacy. 2024 Jan 15;81(2):74-82.
21. Hasselgren C, Oprea TI. Artificial intelligence for drug discovery: are we there yet?. Annual Review of Pharmacology and Toxicology. 2024 Jan 23;64(1):527-50.
22. Tripathi SA, Rohokale MS, Kumar S. Advances in the treatment of cognitive diseases using IOT-based wearable devices. Cognitive Predictive Maintenance Tools for Brain Diseases. 2024 Aug 13:138-57.
23. Amilpur S, Dasari CM. 20 DN-based to identify DTI model potential drug molecules against COVID-19. Handbook of AI-based Models in Healthcare and medicine: approaches, theories, and applications. 2024 Feb 21;397.
24. Hasselgren C, Oprea TI. Artificial intelligence for drug discovery: are we there yet?. Annual Review of Pharmacology and Toxicology. 2024 Jan 23;64(1):527-50.
25. Tropsha A, Isayev O, Varnek A, Schneider G, Cherkasov A. Integrating QSAR modelling and deep learning in drug discovery: the emergence of deep QSAR. Nature Reviews Drug Discovery. 2024 Feb;23(2):141-55.
26. Noor F, Asif M, Ashfaq UA, Qasim M, Tahir ul Qamar M. Machine learning for synergistic network pharmacology: a comprehensive overview. Briefings in bioinformatics. 2023 May;24(3):bbad120.
27. Sankaranarayanan K, Jensen KF. Computer-assisted multistep chemoenzymatic retrosynthesis using a chemical synthesis planner. Chemical Science. 2023;14(23):6467-75.
28. Khan MK, Raza M, Shahbaz M, Hussain I, Khan MF, Xie Z, Shah SS, Tareen AK, Bashir Z, Khan K. The recent advances in the approach of artificial intelligence (AI) towards drug discovery. Frontiers in Chemistry. 2024 May 31; 12:1408740.
29. Dara S, Dhamercherla S, Jadav SS, Babu CM, Ahsan MJ. Machine learning in drug discovery: a review. Artificial intelligence review. 2022 Mar;55(3):1947-99.
30. Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, Blondel M, Prettenhofer P, Weiss R, Dubourg V, Vanderplas J. Scikit-learn: Machine learning in Python. the Journal of machine Learning research. 2011 Nov 1; 12:2825-30.
31. Chen W, Liu X, Zhang S, Chen S. Artificial intelligence for drug discovery: Resources, methods, and applications. Molecular therapy Nucleic acids. 2023 Mar 14; 31:691-702.
32. Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug discovery today. 2019 Mar 1;24(3):773-80.
33. Mayr A, Klambauer G, Unterthiner T, Hochreiter S. DeepTox: toxicity prediction using deep learning. Frontiers in Environmental Science. 2016 Feb 2; 3:80.
34. Reymond JL, Van Deursen R, Blum LC, Ruddigkeit L. Chemical space as a source for new drugs. MedChemComm. 2010;1(1):30-8.
35. Lozano-Diez A, Zazo R, Toledano DT, Gonzalez-Rodriguez J. An analysis of the influence of deep neural network (DNN) topology in bottleneck feature-based language recognition. PloS one. 2017 Aug 10;12(8):e0182580.
36. Takenaka M, Kakue T, Shimobaba T, Ito T. Interactive holographic display for real-time drawing and erasing of 3D point-cloud images with a fingertip. IEEE Access. 2021 Mar 1;9:36766-74.
37. Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. Drug Discov Today. 2021;26(1):80–93.
38. González-Díaz H, Bonet I, Terán C, De Clercq E, Bello R, García MM, Santana L, Uriarte E. ANN-QSAR model for selection of anticancer leads from structurally heterogeneous series of compounds. European journal of medicinal chemistry. 2007 May 1;42(5):580-5.
39. Saini JP, Thakur A, Yadav D. AI driven Innovations in Pharmaceuticals: Optimizing Drug Discovery and Industry Operations. RSC Pharmaceutics. 2025.
40. Benevolent, COVID-19 research, https://www.benevolent.com/about-us/sustainability/covid-19/, (accessed 26.01.2025).
41. Exscientia, Precision Medicine, https://www.exscientia.com/precision-medicine/, (accessed 26.01.2025).
42. M. DeMello, Artificial Intelligence at Pfizer – 3 Use Cases, https://emerj.com/artificial-intelligence-at-pfizer/, (accessed 26.01.2025).
43. Salas M, Petracek J, Yalamanchili P, Aimer O, Kasthuril D, Dhingra S, Junaid T, Bostic T. The use of artificial intelligence in pharmacovigilance: a systematic review of the literature. Pharmaceutical medicine. 2022 Oct;36(5):295-306.
44. Chen Y, Argentinis JE, Weber G. IBM Watson: how cognitive computing can be applied to big data challenges in life sciences research. Clinical therapeutics. 2016 Apr 1;38(4):688-701.
45. Liang L, Hu J, Sun G, Hong N, Wu G, He Y, Li Y, Hao T, Liu L, Gong M. Artificial intelligence-based pharmacovigilance in the setting of limited resources. Drug Safety. 2022 May;45(5):511-9.
46. Deng J, Yang Z, Ojima I, Samaras D, Wang F. Artificial intelligence in drug discovery: applications and techniques. Briefings in Bioinformatics. 2022 Jan 17;23(1).
47. Ramakrishnan L. Harnessing AI for Drug Discovery: The Race to Innovate and Govern. Observer Research Foundation (ORF). Expert Speak; Available from: https://www.orfonline.org/expert-speak/harnessing-ai-for-drug-discovery-the-race-to-innovate-and-govern (accessed 12 February 2026).
48. S, Deepika, Roy S. Artificial intelligence in drug discovery and development: transforming challenges into opportunities. Discover Pharmaceutical Sciences. 2025 Jun 2;1(1):7.
49. DelveInsight. The AI Drug Discovery Revolution: Smarter Science, Faster Therapies, Better Outcomes. DelveInsight Blog. 2025 Oct 22. Available from: https://www.delveinsight.com/blog/ai-in-drug-discovery-revolution (accessed 12 February 2026).
50. BenevolentAI. Life Science Intelligence. BenevolentAI. Available from: https://www.benevolent.com/ (accessed 12 February 2026).
51. Miller S. AstraZeneca and BenevolentAI complete third milestone in their AI-enabled drug discovery cooperation. Pharma Geek. Available from: https://pharma-geek.com/astrazeneca-and-benevolentai-completes-third-milestone-in-their-ai-enabled-drug-discovery-cooperation/ (accessed 12 February 2026).
52. Exscientia Announces First AI-Designed Immuno-Oncology Drug to Enter Clinical Trials.  MedTech Alert. 2021 Apr 9. Available from: https://medtechalert.com/news/clinical-trials/exscientia-announces-first-ai-designed-immuno-oncology-drug-to-enter-clinical-trials/ (accessed 12 February 2026).
53. Nguyen J. How much could Pfizer make from a COVID-19 vaccine? Marketplace. 2020 Nov 12. Available from: https://www.marketplace.org/story/2020/11/12/how-much-could-pfizer-make-from-a-covid-19-vaccine (accessed 12 February 2026).

DOI

10.62226/ijarst20262785

PAGES : 2474-2485 | 10 VIEWS | 5 DOWNLOADS

How do you cite this paper?

Pranjal Ajit Jadhav, Dr. Rupesh Ashok Pingale, Kanchan Gajanan Gawai, Samrudhi Deepak Bhand — “A Next-Generation Drug Discovery Using Artificial Intelligence: Achievements and Challenges.” International Journal of Advanced Research in Science and Technology (IJARST), Volume 15, Issue 8. DOI: 10.62226/ijarst20262785.

Read / Download Full Article